B7-33 (B7-33 (Relaxin Peptide Analog))
A single-chain peptide analog of the hormone relaxin, researched for its anti-fibrotic and cardiovascular/organ-protective effects. Biohackers track it for potential anti-fibrosis and tissue-remodeling benefits; it remains preclinical.
How it works
Selectively activates the relaxin receptor RXFP1 pathway, biasing signaling toward anti-fibrotic effects. It reduces collagen deposition and promotes healthy tissue remodeling in heart, lung, and kidney models without some downsides of full-length relaxin.
Key facts
- Molecular weight: ~3.3 kDa
- Half-life: Short (peptide)
- Bioavailability: Injection (research)
- Storage: Lyophilized: -20°C. Reconstituted: 2-8°C.
Dosing overview
- Typical dose: Not established for humans
- Frequency: Research only
- Duration: Research only
- Route: Injection (research)
Protocol notes
- No validated human dosing exists; all use is experimental and unapproved.
- Animal studies used weight-based injectable dosing for anti-fibrotic effects.
- Included for educational completeness.
Reported benefits
- Anti-fibrotic effects (preclinical)
- Cardiac and organ protection (research)
- Healthy tissue remodeling
- Relaxin-pathway (RXFP1) biased signaling
Possible side effects
- Unknown human safety
- No approved human use
- Unproven efficacy in humans
Research
- B7-33 reduces fibrosis (2016): The relaxin analog B7-33 reduced fibrosis in heart, lung, and kidney models via biased RXFP1 signaling.
Compare B7-33
Research and educational reference only. Not medical advice.